Anti-PD-(L)1 antibodies have been approved for numerous metastatic cancers and recently in adjuvant settings after operation of stage III melanoma or chemoirradation of stage III non-small-cell lung cancer (NSCLC) [2,5,6,7,8,9,10,11,12,13,14,15,16]. The gene discussed is CD274; the disease is metastatic malignant neoplasm.